Moteur de recherche d’entreprises européennes

Financement de l’UE (13,5 M €) : Comprendre les facteurs de risque liés au cancer du poumon et leur impact Hor 01/01/2023 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Comprendre les facteurs de risque liés au cancer du poumon et leur impact

Lung Cancer (LC) is the biggest cancer killer worldwide, with five-year survival following diagnosis varying between 5% to 25%. Though tobacco smoking has long been recognized as the major risk factor for LC, many cases (incl. LC patients that are non-smokers) cannot be explained by this reason. In this sense, LUCIA aims to establish a novel toolbox for discovering and understanding new risk factors that contribute to LC development. The toolbox encompasses the analysis of three aspects: (i) personal risk factors, which include a person’s exposure to chemical pollutants and behavioural and lifestyle factors; (ii) external risk factors, such as urban, built and transport environments, social aspects and climate; and (iii) biological responses to the personal and external risk factors, including changes in genetics, epigenetics, metabolism and aging. Key components of the toolbox for analysing personal and external risk factors include retrospective and prospective cohort databases, AI models, wearable devices, novel non-invasive sensors, and multi-omics. Together, these tools will be used to identify the effects of a wide range of environmental, biological, demographic, community and individual-level risk factors associated with the formation of LC. Molecular changes associated with the risk factors identified by this set of tools will then be validated by cell and molecular biology methods and through in vivo analysis. The impact of the identified personal and external risk factors and the associated biological responses will be then validated in three clinical use cases: general population risk assessment and screening, precision screening of high-risk populations, and digital diagnostics. The resulting evidence within LUCIA will be translated into policymaking recommendations, with the aim to implement them in a screening program for LC. This action is part of the Cancer Mission cluster of projects on ‘Understanding'.


University of Ulster ?
Asociacion Instituto de Investigacion Sanitaria Biobizkaia 838 500 €
Bilbomatica SA 300 125 €
Centre Hospitalier Universitaire de Liege 751 250 €
Consorcio para La Explotacion del Centro Nacional de Analisis Genomico 1 370 534 €
Deutsches Krebsforschungszentrum Heidelberg 583 750 €
Dexai - Etica Artificiale 287 500 €
Emoda Yazilim VE Danismanlik Sanayiticaret Ltd. Sirketi 405 000 €
European Hospital AND Healthcare Federation 199 325 €
Fundacio Centre de Regulacio Genomica 0,00 €
Fundacio Institut de Recerca Biomedica (Irb Barcelona) 813 358 €
Fundacion Centro de Tecnologias de Interaccion Visual y Comunicaciones Vicomtech 744 150 €
Fundacion para La Gestion de La Investigacion en Salud de Sevilla 0,00 €
Latvijas Universitate 599 625 €
Nanose Medical Ltd. 616 340 €
Pronat Indutries Ltd. 603 750 €
Ruprecht-Karls-Universitaet Heidelberg 799 000 €
Servicio Andaluz de Salud 622 500 €
Servicio Vasco de Salud Osakidetza 0,00 €
Technion - Israel Institute OF Technology 2 663 600 €
Technion Research AND Development Foundation Ltd. 0,00 €
Timelex 298 500 €
Universidad Politecnica de Madrid 538 438 €
Yaghma B.V. 481 625 €

https://cordis.europa.eu/project/id/101096473

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : University of Ulster, Coleraine, Royaume Uni.